Hepatitis C vaccine is under clinical development by GeneCure Biotechnologies and currently in Phase I for Hepatitis C. According to GlobalData, Phase I drugs for Hepatitis C have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hepatitis C vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hepatitis C vaccine overview
The vaccine candidate is under development for the treatment of chronic hepatitis C infections. The vaccine candidate comprises of a gene (derived from hepatitis C virus) that is transferred into the host to produce gene products. The vaccine candidate is developed based on lentiviral-based gene transfer technology. It is administered through subcutaneous route.
GeneCure Biotechnologies overview
GeneCure Biotechnologies (GeneCure) is a biotechnology company that focuses on developing gene therapy-based technologies to treat genetic and acquired human diseases. The company offers the development and production of lentiviral vectors and vaccines for various diseases. GeneCure’s pipeline products include Therapeutic HIV-1 vaccine for HIV positive patients; Prophylactic HIV-1 vaccine and Prophylactic HCV vaccine treats high-risk individuals; Therapeutic HCV vaccine which targets chronic HCV; Therapeutic HBV vaccine for chronic HBV. Its products are utilized by researchers and healthcare providers for applications in basic research and clinical studies across the biotechnology and pharmaceutical industries. GeneCure is headquartered in Norcross, Georgia, the US
For a complete picture of Hepatitis C vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
